June 09, 2022

SAN RAMON, CALIF., June 9, 2022—CooperVision, a global leader in myopia management, has announced new data that demonstrate how certified U.S. eye care practices have embraced MiSight® 1 day contact lenses for myopia control. Findings span confidence in the lens, duty to care, and the relationship between the eye care professional (ECP) and patients and parents.

A study of more than 100 U.S. MiSight® 1 day-prescribing ECPs illustrated their trust in the lenses and their potential. 97% are confident that fitting the innovative contact lenses to age-appropriate* patients with myopia will have a positive impact on patients’ long-term vision health,†1 which is a key consideration in myopia management. Each diopter of myopia prevented may lower the risk of myopic maculopathy, glaucoma, and other sight-threatening conditions.2

An encouraging sign of positive change, 96% of these ECPs believe that offering MiSight® 1 day to their age-appropriate patients with myopia demonstrates that they are a leader in providing the best vision care and 97% agree that more ECPs should offer myopia management options.#1

87% of surveyed ECPs further report that myopia management is the standard of care in their practice.¶1 This significant majority aligns with the World Council of Optometry resolution advising all optometrists to incorporate a standard of care for myopia management in their practices.

Though myopia management can represent a significant lifestyle commitment and financial investment for parents of children with myopia, the research indicated that 70% of parents purchase MiSight® 1 day after it is prescribed to their age-appropriate children.4  The parent-ECP relationship also benefits: 87% of ECPs shared that by prescribing MiSight® 1 day to their age-appropriate patients with myopia, they strengthened their relationship with those families as a result.§1

“MiSight® 1 day is the only FDA-approved* soft contact lenses to date proven to slow myopia progression in children, aged 8-12 at the initiation of treatment3±. Its value is even more resounding with this new data,” said Justin Kwan, OD, Senior Manager of Myopia Management for CooperVision. “Myopia control takes teamwork and commitment from ECPs, parents, and children. The ECP confidence and conviction that shines through this data leave no doubt that MiSight® 1 day is enabling and supporting that success.”

To learn more about MiSight® 1 day contact lenses for myopia control* and how to become certified to prescribe the lens, visit https://coopervision.com/practitioner/myopia-management.



* Indications for Use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters(spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.

77% strongly agree, 20% somewhat agree that prescribing MiSight® 1 day contact lenses to age-appropriate patients with myopia will have a positive impact on their patient's long-term vision health.

66% strongly agree, 30% somewhat agree that that offering MiSight® 1 day to their age-appropriate patients with myopia demonstrates that they are a leader in offering the best vision care to their pediatric patients.

# 75% strongly agree, 22% somewhat agree that more ECPs should be involved in practicing myopia management options with their myopic pediatric patients to take care of their long-term vision health.

56% strongly agree, 31% somewhat agree that myopia management is the standard of care in their practice.

§ 50% strongly agree, 37% somewhat agree that prescribing MiSight® 1 day to their age-appropriate patients with myopia has strengthened their relationship with those families.

± Compared to a single vision 1 day lens over a 3 year period.


# # #


About CooperVision
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.

About CooperCompanies
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com

Media Contact
Hannah Barry, Counselor, McDougall Communications
hannah@mcdougallpr.com or +1-585-645-8985


CVI data on file 2022. U.S. CooperVision online survey: ECP MiSight Perspectives; n=101 ECPs that prescribe MiSight® 1 day.

2​​​​​​ Bullimore M. Myopia Control: Why each dioptre matters. BCLA 2019 Poster.

Chamberlain P, et al. A 3-year Randomized Clinical Trial of MiSight® Lenses for Myopia Control. Optom Vis Sci. 2019; 96(8)556-567.